Abstract: SA-PO908
Effect of Statins on Cardiovascular Complications in CKD Patients: A Network Meta-Analysis
Session Information
- CKD: Clinical, Outcomes, Trials - III
November 09, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials
Authors
- Hwang, Seon Deok, Inha University College of Medicine, Incheon, Korea (the Republic of)
- Lee, Seoung woo, Inha University Hospital, Incheon, Korea (the Republic of)
- Lee, Jin ho, Bong Seng Memorial Hospital, Busan, Korea (the Republic of)
Background
It is well known that cardiovascular mortality and morbidity increase in advanced chronic kidney disease (CKD), and that mild to moderate CKD is also associated with an increase in cardiovascular events. Statins have been shown to reduce cardiovascular events, and in this study we investigated the lipid-lowering effect of different statins in CKD patients.
Methods
We searched CENTRAL, MEDLINE, Embase, and Science Citation Index Expanded databases from 1970 until February 2019 to identify cardiac events, cardiac mortality, and all-cause mortality affect in CKD patients according to statin types and doses. We performed direct and indirect network meta-analysis in Bayesian models and generated rankings of the different lipid-lowering agents via generation mixed treatment comparison.
Results
We analyzed the network meta-analysis of 19 studies (N = 45,863) for commonly used statins. Compared with placebos, pravastatin 40 mg groups showed a statistically significant decrease in patient mortality(odds ratio0.66 [95% confidence interval, 0.46 to0.91]). In reducing cardiac events, atorvastatin 80 mg, fluvastatin 40 mg, lovastatin 20 mg, pravastatin 40 mg, and simvastatin 40 mg showed statistically significant effects. In rank probability, pravastatin was ranked first in all-cause mortality rate. In cardiac events, lovastatin, fluvastatin, and pravastatin ranked first, second, and third, respectively.
Conclusion
We found that pravastatin 40mg reduced mortality and cardiovascular events CKD patients receiving statin therapy of hyperlipidemia. In addition, drugs that reduce cardiovascular events appeared effective in the order, lovastatin 20 mg, fluvastatin 40 mg, and pravastatin 40 mg.